Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EASL 2016: Looking For A Competitive Edge In Hepatitis C

This article was originally published in Scrip

Executive Summary

The International Liver Congress hosted by the European Association of the Study of the Liver (EASL) from April 13 to 17 in Barcelona will give hepatitis C drug developers an opportunity to carve out competitive niches before Phase III data for shorter treatment regimens are revealed later in 2016.


Related Content

Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts